Perspective Therapeutics

Perspective Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Perspective Therapeutics (CATX) as of Oct 28, 2026 is -113.56 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 10.46 M USD — a change of -1,185.80% (lower).

EBITDA

-113.56 MUSD

YoY

-1,185.80%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Perspective Therapeutics is 2025 -113.56 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Perspective Therapeutics was 2024 10.46 M USD. It decreases by -1,185.80% lower compared to the previous year.

The Perspective Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-6.73 M USD
Jan 1, 2019
-5.28 M USD
Jan 1, 2020
-3.48 M USD
Jan 1, 2021
-3.44 M USD
Jan 1, 2022
-7.39 M USD
Jan 1, 2023
-15.18 M USD
Jan 1, 2024
10.46 M USD
Jan 1, 2025
-113.56 M USD
The Perspective Therapeutics EBITDA history
YEAREBITDAYoY
-113.56 MUSD-1,185.80%
10.46 MUSD-168.89%
-15.18 MUSD+105.41%
-7.39 MUSD+115.04%
-3.44 MUSD-1.12%
-3.48 MUSD-34.14%
-5.28 MUSD-21.56%
-6.73 MUSD+6.69%
-6.31 MUSD+24.10%
-5.08 MUSD+17.20%
-4.34 MUSD-5.49%
-4.59 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Perspective Therapeutics is -113.56 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Perspective Therapeutics changed from 10.46 M USD to -113.56 M USD, representing a -1,185.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Perspective Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Perspective Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Perspective Therapeutics